NCT04248426 - A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 5, 2020

Primary Completion Date

May 18, 2021

Study Completion Date

May 18, 2021

Conditions

Hepatitis B, Chronic

Interventions

DRUG

ATI-2173

ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.

DRUG

ATI-2173 Placebo

ATI-2173 Placebo is used as an inactive comparator to ATI-2173. It will be dosed as a capsule by mouth.

Trial Locations (3)

H3P 3P1

Altasciences, Montreal

Unknown

"Republican Clinical Hospital Timofei Mosneaga Arensia EM Unit", Chisinau

"Medical Center of Limited Liability Company Harmoniya krasy Department of Clinical Trials", Kyiv